{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:58:22Z","timestamp":1769576302468,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,8,11]],"date-time":"2018-08-11T00:00:00Z","timestamp":1533945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Cristalia Chemical and Pharmaceutical Products Ltda"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Excessive sweating is a clinical condition that can be improved with type-A botulinum toxin (BTX-A).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate and compare the largest diameter of sweating inhibition halo (SIH) of 5 different commercially available BTX-A, in five different doses, in a 6-month-long clinical evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-five adult female volunteers were injected in the dorsal trunk area with both 100 units (100UI) and 500 units (500UI) BTX-A products, reconstituted in a ratio of 1:2.5 IU, respectively. Products were applied in five different concentrations (1:2.5U, 2:5U, 3:7.5U, 4:10U, and 5:12.5U). After 30, 60, 90, 120, 150, and 180 days, a starch-iodine test was performed to obtain the largest diameter of each SIH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The higher the number of units used, the larger the SIH p &lt; 0.05 for all BTX-A. However, Botox\u00ae, Botulift\u00ae, Dysport\u00ae, and Prosigne\u00ae have pretty likewise SIH along the study, with some few differences for some doses and months between one and another. However, Xeomin\u00ae is the BTX-A with the smallest SIH, in comparison with all others, in any dose and period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Differences were observed among all brands of BTX-As, based on dose and time after injection. Xeomin\u00ae provides the smallest SIH in comparison with others BTX-A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Level of Evidence: 2<\/jats:title><jats:p\/><\/jats:sec>","DOI":"10.1093\/asj\/sjy207","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:19:16Z","timestamp":1539202756000},"page":"993-1004","source":"Crossref","is-referenced-by-count":8,"title":["Six-Month Comparative Analysis Monitoring the Progression of the Largest Diameter of the Sweating Inhibition Halo of Different Botulinum Toxins Type-A"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-6840","authenticated-orcid":false,"given":"Adilson","family":"da Costa","sequence":"first","affiliation":[{"name":"Instituto de Assist\u00eancia M\u00e9dica ao Servidor P\u00fablico, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisangela Samartin Pegas","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareth","family":"de Oliveira Pereira","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Borba Calixto","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"F\u00e1varo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissa Sabino","family":"de Matos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00edsa Saddi","family":"Tannous","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Oliveira Parra","family":"Duarte","sequence":"additional","affiliation":[{"name":"KOLderma Clinical Trials Institute, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Silva","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"1","key":"2019091011333709900_CIT0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1503\/cmaj.1040708","article-title":"Focal hyperhidrosis: diagnosis and management","volume":"172","author":"Haider","year":"2005","journal-title":"CMAJ"},{"issue":"9","key":"2019091011333709900_CIT0002","first-page":"651","article-title":"Management of Frey syndrome using botulinum neurotoxin: a case report","volume":"75","author":"Ng","year":"2009","journal-title":"J Can Dent Assoc"},{"issue":"3","key":"2019091011333709900_CIT0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archsurg.1994.01420270015004","article-title":"Endoscopic transthoracic sympathectomy in the treatment of primary hyperhidrosis. A review of 290 sympathectomies","volume":"129","author":"Shachor","year":"1994","journal-title":"Arch Surg"},{"issue":"1","key":"2019091011333709900_CIT0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J Dermatol"},{"issue":"2","key":"2019091011333709900_CIT0005","first-page":"147","article-title":"Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis","volume":"1","author":"Rusciani","year":"2002","journal-title":"J Drugs Dermatol"},{"key":"2019091011333709900_CIT0006","first-page":"739","article-title":"High-dose botulinum type A for axillary hyperidrosis markedly prolongs the relapse free interval","volume":"51","author":"Wollina","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2019091011333709900_CIT0007","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2340\/00015555-0490","article-title":"Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis","volume":"88","author":"Rystedt","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2019091011333709900_CIT0008","first-page":"1","article-title":"Botulinum toxin products overview","volume":"13","author":"Carruthers","year":"2008","journal-title":"Skin Therapy Lett"},{"key":"2019091011333709900_CIT0009","first-page":"725","article-title":"Profile of Xeomin\u00ae (incobotulinumtoxinA) for the treatment of blepharospasm","volume":"5","author":"Park","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"2019091011333709900_CIT0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNF.0b013e3181c46f48","article-title":"A prospective, randomized, double-blind study comparing the efficacy and safety of type A botulinum toxins Botox and Prosigne in the treatment of cervical dystonia","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"2019091011333709900_CIT0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D394R5S9S1","article-title":"Comparative study of the diffusion of five botulinum toxins type-A in five dosages of use: are there differences amongst the commercially-available products","volume":"18","author":"Costa","year":"2012","journal-title":"Dermatol Online J"},{"issue":"3","key":"2019091011333709900_CIT0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","article-title":"Double-blind, randomized, comparative study of Meditoxin vs Botox in the treatment of essential blepharospasm","volume":"23","author":"Yoon","year":"2009","journal-title":"Korean J Ophthalmol"},{"key":"2019091011333709900_CIT0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17429590701523794","article-title":"Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications","volume":"9","author":"de Almeida","year":"2007","journal-title":"J Cosmet Laser Ther"},{"issue":"5","key":"2019091011333709900_CIT0014","first-page":"573","article-title":"Durability of three different types of hyaluronic acid fillers in skin: are there differences among biphasic, monophasic monodensified, and monophasic polydensified products","volume":"37","author":"da Costa","year":"2017","journal-title":"Aesthet Surg J"},{"issue":"7","key":"2019091011333709900_CIT0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archdermatol.2009.128","article-title":"Increasing the field effects of similar doses of Clostridium botulinum type A toxin-hemagglutinin complex in the treatment of compensatory hyperhidrosis","volume":"145","author":"Hexsel","year":"2009","journal-title":"Arch Dermatol"},{"issue":"12","key":"2019091011333709900_CIT0016","doi-asserted-by":"crossref","first-page":"e4066","DOI":"10.1371\/journal.pone.0004066","article-title":"Aging alters functionally human dermal papillary fibroblasts but not reticular fibroblasts: a new view of skin morphogenesis and aging","volume":"3","author":"Mine","year":"2008","journal-title":"PLoS One"},{"key":"2019091011333709900_CIT0017","volume-title":"Anatomy Atlases: Atlas of Microscopic Anatomy: Section 1 - Cells"},{"key":"2019091011333709900_CIT0018","volume-title":"Purification of Clostridium botulinum Type A Neurotoxin"},{"key":"2019091011333709900_CIT0019","volume-title":"US9512418B2 - Method for production of botulinum toxin - Google Patents"},{"key":"2019091011333709900_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/asj\/sjx076","article-title":"Cosmetic surgery national data bank statistics","volume":"37","year":"2017","journal-title":"Aesthet Surg J"},{"key":"2019091011333709900_CIT0021","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/01.DSS.0000452649.99141.69","article-title":"Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis","volume":"41","author":"Hexsel","year":"2015","journal-title":"Dermatol Surg"},{"issue":"2","key":"2019091011333709900_CIT0022","first-page":"73","article-title":"Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion","volume":"117","author":"Lim","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2019091011333709900_CIT0023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1529-8019.2010.01378.x","article-title":"Botulinum toxin type A for aging face and aesthetic uses","volume":"24","author":"Hexsel","year":"2011","journal-title":"Dermatol Ther"},{"issue":"1","key":"2019091011333709900_CIT0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00042728-200801000-00009","article-title":"A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A","volume":"34","author":"Hexsel","year":"2008","journal-title":"Dermatol Surg"},{"key":"2019091011333709900_CIT0025","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/01.DSS.0000452645.76270.88","article-title":"Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study","volume":"41","author":"Hexsel","year":"2015","journal-title":"Dermatol Surg"},{"issue":"3","key":"2019091011333709900_CIT0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J Neural Transm (Vienna)"},{"issue":"11","key":"2019091011333709900_CIT0027","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"2019091011333709900_CIT0028","first-page":"725","article-title":"Profile of Xeomin\u00ae (incobotulinumtoxinA) for the treatment of blepharospasm","volume":"5","author":"Park","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2019091011333709900_CIT0029","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1524-4725.2006.32330.x","article-title":"Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis","volume":"33","author":"Trindade de Almeida","year":"2007","journal-title":"Dermatol Surg"},{"issue":"2","key":"2019091011333709900_CIT0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaad.2011.08.011","article-title":"Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial","volume":"67","author":"Hexsel","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2019091011333709900_CIT0031","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jamadermatol.2013.6440","article-title":"Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial","volume":"149","author":"Hexsel","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2019091011333709900_CIT0032","first-page":"s31","article-title":"Practical applications of a new botulinum toxin","volume":"9","author":"Hexsel","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"2019091011333709900_CIT0033","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archderm.140.11.1351","article-title":"Effect of volume and concentration on the diffusion of botulinum exotoxin A","volume":"140","author":"Hsu","year":"2004","journal-title":"Arch Dermatol"},{"issue":"2","key":"2019091011333709900_CIT0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher","year":"2012","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"2019091011333709900_CIT0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.det.2014.06.013","article-title":"Botulinum toxin for axillary hyperhidrosis","volume":"32","author":"de Almeida","year":"2014","journal-title":"Dermatol Clin"},{"issue":"2","key":"2019091011333709900_CIT0036","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jaad.2008.12.028","article-title":"Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine","volume":"62","author":"Karsai","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2019091011333709900_CIT0037","first-page":"719","article-title":"Potency equivalence of botulinum toxin preparations","volume":"87","author":"Hambleton","year":"1994","journal-title":"J R Soc Med"},{"issue":"8","key":"2019091011333709900_CIT0038","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","article-title":"Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study","volume":"20","author":"Marchetti","year":"2005","journal-title":"Mov Disord"},{"key":"2019091011333709900_CIT0039","first-page":"66","article-title":"Equipotent doses of botulinum toxin type A products share same radius of action","volume":"9","author":"Hexsel","year":"2005","journal-title":"Dermatol Times"},{"issue":"2","key":"2019091011333709900_CIT0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mds.26085","article-title":"Dysport and botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study","volume":"30","author":"Ji","year":"2015","journal-title":"Mov Disord"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/asj\/article-pdf\/39\/9\/993\/29196887\/sjy207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T21:49:59Z","timestamp":1693950599000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/39\/9\/993\/5070428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,10,10]]},"published-print":{"date-parts":[[2019,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjy207","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2018,10,10]]}}}